- Home
- NYT vs BMRN Comparison
NYT vs BMRN Comparison
Compare NYT & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NYT | BMRN |
|---|---|---|
| Founded | 1851 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 11.4B |
| IPO Year | 1994 | 1999 |
Fundamental Metrics
Financial Performance| Metric | NYT | BMRN |
|---|---|---|
| Price | $75.29 | $59.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 18 |
| Target Price | $72.14 | ★ $88.22 |
| AVG Volume (30 Days) | 1.7M | ★ 1.7M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.16% | N/A |
| EPS Growth | ★ 18.08 | N/A |
| EPS | 0.54 | 0.54 |
| Revenue | ★ $1,783,639,000.00 | $1,313,646,000.00 |
| Revenue This Year | $10.58 | $15.02 |
| Revenue Next Year | $6.98 | $12.23 |
| P/E Ratio | $140.02 | ★ $110.61 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $51.03 | $49.26 |
| 52 Week High | $87.10 | $66.28 |
Technical Indicators
Market Signals| Indicator | NYT | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 56.27 | 57.85 |
| Support Level | $72.59 | $54.24 |
| Resistance Level | $77.28 | $60.22 |
| Average True Range (ATR) | 1.93 | 1.41 |
| MACD | 0.51 | -0.06 |
| Stochastic Oscillator | 79.38 | 70.64 |
Price Performance
Historical ComparisonAbout NYT New York Times Company (The)
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as NYTimes and various smartphone applications. The company derives revenue from subscriptions, advertising, and other sources, where the majority of its revenue is generated through subscriptions, which consist of income from standalone and multiproduct bundle subscriptions to its digital products and subscriptions to and single-copy and bulk sales of print products.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.